Pharmacoepidemiology studies

The extensive pharmacy records and other data in our electronic health record system uniquely position us to examine long-term outcomes of medication use. We collaborate with federal agencies to study medication safety and participate in the Centers for Education and Research on Therapeutics to conduct research on and share information about the best use of drugs, medical devices, and biological products.

Cardiovascular toxicity following aromatase inhibitor use

The aim of this cohort is to assess the risk of cardiovascular disease associated with endocrine treatments for breast cancer.

Principal Investigator:

Reina Haque, PhD, MPH

Funding Source:

California Breast Cancer Research Program (CBCRP)

Funding Years:

2013 - 2017

Database Cohort Study to Assess the Risk of Serious Angioedema in Assocation with Sacubitril/Valsartan use in Black Patients with Heart Failuer in the U.S.

The overall goal of this study is to provide real-world estimates of the incidence of angioedema among both HF patients initiating sacubitril/valsartan and HF patients initiating an ACEI, with a primary focus on Black patients.

Site Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

Novartis Pharmaceuticals Corporation

Funding Years:

2016 - 2020

Glargine Insulin and Risk of Cancer in Cohort of Patients with Diabetes

The goal of this project was to understand the cancer risks associated with use of glargine, an insulin medication. This study compared the risk of several types of cancer among individuals with diabetes who used glargine to those using NPH, another type of insulin.

Site Principal Investigator:

Kim N. Danforth, ScD, MPH

Funding Source:

Sanofi-Aventis U.S. LLC

Funding Years:

2010 - 2013

HEPLISAV-B Post Marketing Surveillance Study

The primary objective of this post-marketing observational surveillance study is to compare the occurrence of acute myocardial infarction (AMI) in recipients of HEPLISAV-B with recipients of another hepatitis B vaccine.

Principal Investigator:

Steven J. Jacobsen, MD, PhD

Funding Source:

Dynavax Technologies

Funding Years:

2017 - 2020

Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment

Evaluating the effect of treating mild-to-moderate hypertension in pregnancy, compare the risks of clinically important outcomes with different medications, and determine whether the benefits and risks vary by maternal race/ethnicity or obesity status.

Site Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

National Institute of Child Health and Human Development (NICHD)

Funding Years:

2015 - 2019

Retrospective Cohort Study of Risk of Hip Fractures Associated with High Dose, Long-term Proton Pump Inhibitor (HD-PPI) Use and Cytochrome P450 Pharmacogenomics

The main goals of this study are to conduct two related cohort studies intended to address questions related to the association between PPI and HD-PPI use in a setting of complex medication usage patterns and to conduct a pharmacogenetics study exploring potential modification of the relationship between PPI use and hip fracture risk by CYP2C19 genotype.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Food and Drug Administration (FDA)

Funding Years:

2014 - 2018

The Comparative effectiveness of Warfarin and New Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism

The overall goal of this project is to provide information on the benefits and harms comparing different treatment options for the extended treatment of VTE, information that can be used by clinicians and patients in deciding on the optimal treatment strategy.

Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

Patient-Centered Outcomes Research Institute (PCORI)

Funding Years:

2016 - 2020

Vaccine Safety Datalink Project-CDC

VSD is a multi-site study of vaccine safety in a network of managed care organizations from across the US. The VSD project allows for planned immunization safety studies as well as timely investigations of hypotheses that arise from review of medical literature, reports to the Vaccine Adverse Event Reporting System (VAERS), changes in immunization schedules, or the introduction of new vaccines.

:

Hung Fu Tseng, PhD, MPH

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2017 - 2022